Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gazzard

Showing results (81-90 of 221) with videos related to

Pageof 23
Sort By:
HIV Medicine|July 2, 2008
Indicator disease-guided testing for HIV--the next step for Europe?B Gazzard, N Clumeck, A d'Arminio Monforte, et al.
Respiratory Medicine|November 1, 1991
A comparison of several agents with two delivery systems for the prevention of airway narrowing induced by nebulised pentamidine isethionateT R Leigh, J Wiggins, B Gazzard, et al.
Clinical and Experimental Immunology|August 2, 2006
Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortalityJ Stebbing, M Bower, S Mandalia, et al.
Postgraduate Medical Journal|May 9, 2006
A single centre cohort experience with a new once daily antiretroviral drugJ Stebbing, M Bower, P Holmes, et al.
Journal of Clinical Pathology|August 1, 1992
Adenovirus infection of the large bowel in HIV positive patientsA Maddox, N Francis, J Moss, et al.
International Journal of STD & AIDS|January 1, 1994
How should an AIDS diagnosis be given? The views of patientsA Pergami, J Catalan, N Hulme, et al.
British Journal of Clinical Pharmacology|March 1, 1985
The effect of secoverine hydrochloride on stimulated sigmoid motility: a double-blind, placebo controlled cross-over study in irritable bowel syndromeM Ehsanullah, D A Lee, T Williams, et al.
HIV Medicine|May 7, 2005
The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once dailyM-Y Tung, S Mandalia, M Bower, et al.
Clinical and Experimental Immunology|November 25, 2003
Loss of the CD56hiCD16- NK cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-1: partial recovery by human growth hormoneM R Goodier, N Imami, G Moyle, et al.
International Journal of STD & AIDS|July 1, 1995
Kaposi's sarcoma in the kidneyR C Pollok, N Francis, S Cliff, et al.
Pageof 23

Showing results (81-90 of 221) with videos related to

Sort By:
Pageof 23
HIV Medicine|July 2, 2008
Indicator disease-guided testing for HIV--the next step for Europe?B Gazzard, N Clumeck, A d'Arminio Monforte, et al.
Respiratory Medicine|November 1, 1991
A comparison of several agents with two delivery systems for the prevention of airway narrowing induced by nebulised pentamidine isethionateT R Leigh, J Wiggins, B Gazzard, et al.
Clinical and Experimental Immunology|August 2, 2006
Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortalityJ Stebbing, M Bower, S Mandalia, et al.
Postgraduate Medical Journal|May 9, 2006
A single centre cohort experience with a new once daily antiretroviral drugJ Stebbing, M Bower, P Holmes, et al.
Journal of Clinical Pathology|August 1, 1992
Adenovirus infection of the large bowel in HIV positive patientsA Maddox, N Francis, J Moss, et al.
International Journal of STD & AIDS|January 1, 1994
How should an AIDS diagnosis be given? The views of patientsA Pergami, J Catalan, N Hulme, et al.
British Journal of Clinical Pharmacology|March 1, 1985
The effect of secoverine hydrochloride on stimulated sigmoid motility: a double-blind, placebo controlled cross-over study in irritable bowel syndromeM Ehsanullah, D A Lee, T Williams, et al.
HIV Medicine|May 7, 2005
The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once dailyM-Y Tung, S Mandalia, M Bower, et al.
Clinical and Experimental Immunology|November 25, 2003
Loss of the CD56hiCD16- NK cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-1: partial recovery by human growth hormoneM R Goodier, N Imami, G Moyle, et al.
International Journal of STD & AIDS|July 1, 1995
Kaposi's sarcoma in the kidneyR C Pollok, N Francis, S Cliff, et al.
Pageof 23